Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Abstract

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib versus imatinib in adults with newly diagnosed (≤6 months) CP CML after >30 months from accrual completion. Among patients randomized to bosutinib 500 mg/d (n = 250) or imatinib 400 mg/d (n = 252), 248 and 251, respectively, received ≥1 dose of study treatment. Adverse events (AEs; any grade) with bosutinib versus imatinib were significantly more common for certain gastrointestinal events (diarrhea, 70% vs. 26%; P < 0.001; vomiting, 33% vs. 16%; P < 0.001), alanine aminotransferase (33% vs. 9%; P < 0.001) and aspartate aminotransferase (28% vs. 10%; P < 0.001) elevations, and pyrexia (19% vs. 12%; P = 0.046). AEs significantly less common with bosutinib included edema (periorbital, 2% vs. 14%; P < 0.001; peripheral, 5% vs. 12%; P = 0.006), musculoskeletal (myalgia, 5% vs. 12%; P = 0.010; muscle cramps, 5% vs. 22%; P < 0.001; bone pain, 4% vs. 11%; P = 0.003), increased creatine phosphokinase (8% vs. 20%; P < 0.001), neutropenia (13% vs. 30%; P < 0.001), and leukopenia (9% vs. 22%; P < 0.001). Between-group differences in the incidence of cardiac and vascular AEs were not significant. Diarrhea was typically transient, mostly Grade 1/2, occurring early during treatment, and was manageable with antidiarrheal medication. Despite higher rates of aminotransferase elevation with bosutinib, events were managed in most patients with dose modification and/or concomitant medication. Bosutinib had a manageable safety profile distinct from that of imatinib in patients with newly diagnosed CP CML.

• Authors: Carlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, Anna Dmoszynska, Raymond S Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M Kantarjian, Tim H Brümmendorf
• Journal: American journal of hematology (Am J Hematol) Vol. 89 Issue 10 Pg. 947-53 (Oct 2014) ISSN: 1096-8652 [Electronic] United States
• PMID: 24944159 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: © 2014 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.

Chemical References

• Aniline Compounds
• Antineoplastic Agents
• Benzamides
• Nitriles
• Piperazines
• Pyrimidines
• Quinolines
• bosutinib
• Imatinib Mesylate
• Aspartate Aminotransferases
• Alanine Transaminase

Topics

• Alanine Transaminase (blood)
• Aniline Compounds (administration & dosage, adverse effects)
• Antineoplastic Agents (administration & dosage, adverse effects)
• Aspartate Aminotransferases (blood)
• Benzamides (administration & dosage, adverse effects)
• Diarrhea (blood, chemically induced)
• Female
• Fever (blood, chemically induced)
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood, pathology)
• Male
• Middle Aged
• Muscle Cramp (blood, chemically induced)
• Myalgia (blood, chemically induced)
• Nitriles (administration & dosage, adverse effects)
• Pain (blood, chemically induced)
• Piperazines (administration & dosage, adverse effects)
• Pyrimidines (administration & dosage, adverse effects)
• Quinolines (administration & dosage, adverse effects)
• Vomiting (blood, chemically induced)